# SUPERNUS PHARMACEUTICALS, INC.

Summary updated: 2026-10-02T12:13:13.752853Z
Canonical: https://finbar.com/research/companies/supernus-pharmaceuticals-inc

## Overview

Supernus Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing treatments for central nervous system diseases, including neurological and psychiatric conditions. Its portfolio includes therapies for ADHD, Parkinson’s disease, epilepsy, migraine and postpartum depression, among other conditions; defining products include Qelbree, GOCOVRI, Oxtellar XR, APOKYN and ZURZUVAE. [1](https://app.finbar.com/go?id=P28157026)[2](https://app.finbar.com/go?id=P70098054) The company describes its mission as developing innovative treatments for neurological and psychiatric disorders with a patient-focused approach. [3](https://www.supernus.com/about-us)

Supernus’s commercial business is principally U.S.-focused. It reported 2025 revenue of $719.0 million and 778 full-time U.S. employees at year-end. [4](https://ir.supernus.com/news-releases/news-release-details/supernus-announces-record-fourth-quarter-and-full-year-2025)[5](https://app.finbar.com/go?id=P29366535) The company began operations in 2005, is headquartered in Rockville, Maryland, and has been publicly traded on Nasdaq since 2012. [6](https://app.finbar.com/go?id=P11142395)
[1](https://app.finbar.com/go?id=P28157026)[2](https://app.finbar.com/go?id=P70098054)[3](https://www.supernus.com/about-us)[4](https://ir.supernus.com/news-releases/news-release-details/supernus-announces-record-fourth-quarter-and-full-year-2025)[5](https://app.finbar.com/go?id=P29366535)[6](https://app.finbar.com/go?id=P11142395)[3](https://www.supernus.com/about-us)[4](https://ir.supernus.com/news-releases/news-release-details/supernus-announces-record-fourth-quarter-and-full-year-2025)

## Products & services

Supernus’s marketed portfolio includes Qelbree (viloxazine extended-release capsules), an ADHD treatment for adults and children aged 6 and older; GOCOVRI (amantadine extended-release capsules), taken once daily at bedtime for dyskinesia in Parkinson’s disease patients receiving levodopa and as adjunctive treatment for “OFF” episodes; and Trokendi XR (topiramate extended-release capsules), a once-daily product for epilepsy and migraine. [7](https://www.supernus.com/commercial-products)[8](https://www.gocovri.com/)[9](https://app.finbar.com/go?id=P145644895)

Its Parkinson’s disease products also include ONAPGO, a continuous subcutaneous apomorphine infusion for motor fluctuations in adults with advanced disease, and APOKYN, an apomorphine injection pen used as an adjunct to levodopa/carbidopa for “OFF” episodes. Oxtellar XR (oxcarbazepine extended-release) is a once-daily treatment for partial-onset seizures in adults and children aged 6 and older. ZURZUVAE (zuranolone) is an oral, once-daily 14-day treatment for postpartum depression in adults; U.S. commercialization is shared with Biogen, with operating profits and losses shared equally. [10](https://www.onapgo.com/)[11](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021264s025lbl.pdf)[12](https://app.finbar.com/go?id=P145644898)[13](https://app.finbar.com/go?id=P114435910)[14](https://app.finbar.com/go?id=P75311284)

For the six months ended June 30, 2026, net sales were $167.1 million for Qelbree, $72.8 million for GOCOVRI, $21.9 million for ONAPGO, $17.9 million for Trokendi XR, $16.2 million for Oxtellar XR and $14.1 million for APOKYN. ZURZUVAE generated $63.0 million in collaboration revenue and is reported separately from net product sales. In 2025, Qelbree, GOCOVRI, APOKYN, Trokendi XR and Oxtellar XR accounted for 49%, 23%, 8%, 7% and 6% of net product sales, respectively. [15](https://app.finbar.com/go?id=T16665204)[16](https://app.finbar.com/go?id=T6362400)
[9](https://app.finbar.com/go?id=P145644895)[12](https://app.finbar.com/go?id=P145644898)[13](https://app.finbar.com/go?id=P114435910)[14](https://app.finbar.com/go?id=P75311284)[15](https://app.finbar.com/go?id=T16665204)[16](https://app.finbar.com/go?id=T6362400)[7](https://www.supernus.com/commercial-products)[8](https://www.gocovri.com/)[10](https://www.onapgo.com/)[11](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021264s025lbl.pdf)

## Geographic presence

Supernus Pharmaceuticals’ commercial-product revenue is derived primarily from sales in the United States. The company reports one operating segment, but does not disclose a country-by-country revenue breakdown or a precise percentage of revenue attributable to the U.S. [17](https://app.finbar.com/go?id=P46279788)[18](https://app.finbar.com/go?id=P145644731)

Its principal executive offices are in Rockville, Maryland. For ZURZUVAE, Biogen is responsible for territories outside the U.S., except Japan, South Korea, and Taiwan; this describes the collaboration’s territorial responsibilities, not evidence of Supernus’s own offices or direct sales in those markets. [19](https://app.finbar.com/go?id=P75148254)[20](https://app.finbar.com/go?id=P93289535) ONAPGO is manufactured in Europe and packaged in the U.S. [21](https://app.finbar.com/go?id=P145644616)
[17](https://app.finbar.com/go?id=P46279788)[18](https://app.finbar.com/go?id=P145644731)[19](https://app.finbar.com/go?id=P75148254)[20](https://app.finbar.com/go?id=P93289535)[21](https://app.finbar.com/go?id=P145644616)

## Business segments

Supernus Pharmaceuticals reports one operating segment and one reportable segment: its consolidated business, which derives revenue primarily from U.S. sales of commercial products. It does not report separate business or therapeutic segments, so the product percentages below are sales mix—not separate segment contributions. [17](https://app.finbar.com/go?id=P46279788)[18](https://app.finbar.com/go?id=P145644731)

For 2025, net product sales were distributed as follows: Qelbree 49%, GOCOVRI 23%, APOKYN 8%, Trokendi XR 7%, Oxtellar XR 6%, ONAPGO 3%, and other products 4%. These product-level shares sum to 100% of net product sales. [16](https://app.finbar.com/go?id=T6362400)
[17](https://app.finbar.com/go?id=P46279788)[18](https://app.finbar.com/go?id=P145644731)[16](https://app.finbar.com/go?id=T6362400)[16](https://app.finbar.com/go?id=T6362400)[16](https://app.finbar.com/go?id=T6362400)[16](https://app.finbar.com/go?id=T6362400)[16](https://app.finbar.com/go?id=T6362400)[16](https://app.finbar.com/go?id=T6362400)[16](https://app.finbar.com/go?id=T6362400)[16](https://app.finbar.com/go?id=T6362400)

## Company history

Supernus began operations in 2005 after acquiring substantially all assets of Shire Laboratories; founder Jack A. Khattar has led the company as president and CEO since its formation. The company went public in 2012, then launched Oxtellar XR and Trokendi XR in 2013, establishing its commercial epilepsy business. [6](https://app.finbar.com/go?id=P11142395)[22](https://www.supernus.com/our-leadership)[23](https://app.finbar.com/go?id=P189831090)

The company expanded its pipeline in 2018 by acquiring rights to the investigational epilepsy treatment SPN-817 from Biscayne Neurotherapeutics, and broadened Oxtellar XR’s use in 2019. [24](https://app.finbar.com/go?id=P41627667)[25](https://ir.supernus.com/news-releases/news-release-details/supernus-to-acquire-biscayne-neurotherapeutics)[26](https://app.finbar.com/go?id=P3300054) In 2020 it acquired US WorldMeds’ CNS portfolio, adding products including APOKYN, MYOBLOC and XADAGO. [27](https://www.sec.gov/Archives/edgar/data/1356576/000135657620000023/ex99104282020.htm)[28](https://supernus.gcs-web.com/news-releases/news-release-details/supernus-announces-second-quarter-2020-financial-results)

Supernus launched Qelbree for pediatric ADHD in 2021 and received FDA approval for adult ADHD in 2022; it also completed its acquisition of Adamas Pharmaceuticals in 2021, adding Parkinson’s disease products including GOCOVRI. [13](https://app.finbar.com/go?id=P114435910)[29](https://ir.supernus.com/news-releases/news-release-details/supernus-pharmaceuticals-completes-acquisition-adamas) In 2025, it launched ONAPGO following FDA approval for advanced Parkinson’s disease and completed its acquisition of Sage Therapeutics, adding ZURZUVAE and a late-stage development candidate. [30](https://app.finbar.com/go?id=P85580283)[31](https://app.finbar.com/go?id=P89723555)
[6](https://app.finbar.com/go?id=P11142395)[23](https://app.finbar.com/go?id=P189831090)[24](https://app.finbar.com/go?id=P41627667)[26](https://app.finbar.com/go?id=P3300054)[13](https://app.finbar.com/go?id=P114435910)[30](https://app.finbar.com/go?id=P85580283)[31](https://app.finbar.com/go?id=P89723555)[22](https://www.supernus.com/our-leadership)[25](https://ir.supernus.com/news-releases/news-release-details/supernus-to-acquire-biscayne-neurotherapeutics)[27](https://www.sec.gov/Archives/edgar/data/1356576/000135657620000023/ex99104282020.htm)[28](https://supernus.gcs-web.com/news-releases/news-release-details/supernus-announces-second-quarter-2020-financial-results)[29](https://ir.supernus.com/news-releases/news-release-details/supernus-pharmaceuticals-completes-acquisition-adamas)

## Sources

1. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P28157026)
2. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P70098054)
3. [www.supernus.com](https://www.supernus.com/about-us)
4. [ir.supernus.com](https://ir.supernus.com/news-releases/news-release-details/supernus-announces-record-fourth-quarter-and-full-year-2025)
5. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P29366535)
6. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P11142395)
7. [www.supernus.com](https://www.supernus.com/commercial-products)
8. [www.gocovri.com](https://www.gocovri.com/)
9. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145644895)
10. [www.onapgo.com](https://www.onapgo.com/)
11. [www.accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021264s025lbl.pdf)
12. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145644898)
13. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P114435910)
14. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P75311284)
15. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16665204)
16. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T6362400)
17. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P46279788)
18. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145644731)
19. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P75148254)
20. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P93289535)
21. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145644616)
22. [www.supernus.com](https://www.supernus.com/our-leadership)
23. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2015 Y)](https://app.finbar.com/go?id=P189831090)
24. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P41627667)
25. [ir.supernus.com](https://ir.supernus.com/news-releases/news-release-details/supernus-to-acquire-biscayne-neurotherapeutics)
26. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P3300054)
27. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1356576/000135657620000023/ex99104282020.htm)
28. [supernus.gcs-web.com](https://supernus.gcs-web.com/news-releases/news-release-details/supernus-announces-second-quarter-2020-financial-results)
29. [ir.supernus.com](https://ir.supernus.com/news-releases/news-release-details/supernus-pharmaceuticals-completes-acquisition-adamas)
30. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P85580283)
31. [SUPERNUS PHARMACEUTICALS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P89723555)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.